|
Generally, pharmaceutical companies compete to develop the next
blockbuster drug for diseases that affect large numbers of people.
So, when Novartis in May trumpeted
an advance in tackling Muckle-Wells syndrome, a rare inflammatory disease which
causes skin rashes, it took some industry analysts by surprise.
|
[CML] A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com
